South Korean precision medicine company eGnome is accelerating its entry into the European market through its third-generation microbiome analysis technology. The company is preparing to sign a formal agreement with Medicana, a leading private hospital group in Türkiye, to launch personalized microbiome-based healthcare services. As part of the collaboration, eGnome will provide its advanced analysis platform to Medicana hospitals and offer AI-powered solutions such as disease prediction and personalized probiotics. eGnome also plans to expand partnerships into joint research, clinical data sharing, and functional food development, targeting broader market penetration across Europe and the Middle East.